Anticoagulation in the management of ST-segment elevation myocardial infarction

Paul P. Dobesh, Toby C. Trujillo

Research output: Contribution to journalReview article

Abstract

Patients with ST-segment elevation myocardial infarction (STEMI) require immediate reperfusion therapy in order to salvage ischemic myocardial tissue and reduce mortality. Reperfusion therapy can be provided mechanically with primary percutaneous coronary intervention (PCI), or pharmacologically with fibrinolysis. Regardless of the reperfusion strategy selected, the appropriate use of anticoagulant therapy is critical to its success. There have been a number of clinical trials evaluating the different anticoagulants in patients with STEMI, as well as recent updates to the guidelines for management of patients with STEMI and on the use of PCI. When making clinical decisions on the use of anticoagulant therapy in the management of patients with STEMI, it is important to not only understand the contents of these consensus guidelines but to also have an appreciation of the details of the clinical trials that have evaluated the different anticoagulants. In this review, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with STEMI as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in patients with STEMI undergoing either mechanical or pharmacologic reperfusion.

Original languageEnglish (US)
Pages (from-to)335-343
Number of pages9
JournalJournal of Pharmacy Practice
Volume23
Issue number4
DOIs
StatePublished - Aug 1 2010

Fingerprint

Anticoagulants
Reperfusion
Guidelines
Percutaneous Coronary Intervention
Therapeutics
Clinical Trials
Fibrinolysis
ST Elevation Myocardial Infarction
Mortality

Keywords

  • acute coronary syndrome
  • anticoagulation
  • bivalirudin
  • cardiology
  • coronary artery disease
  • enoxaparin
  • fibrinolysis
  • fondaparinux
  • low-molecular-weight heparin
  • myocardial infarction
  • percutaneous coronary intervention
  • unfractionated heparin

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Anticoagulation in the management of ST-segment elevation myocardial infarction. / Dobesh, Paul P.; Trujillo, Toby C.

In: Journal of Pharmacy Practice, Vol. 23, No. 4, 01.08.2010, p. 335-343.

Research output: Contribution to journalReview article

@article{04320e78a9744838a7cc83b787cc4e3a,
title = "Anticoagulation in the management of ST-segment elevation myocardial infarction",
abstract = "Patients with ST-segment elevation myocardial infarction (STEMI) require immediate reperfusion therapy in order to salvage ischemic myocardial tissue and reduce mortality. Reperfusion therapy can be provided mechanically with primary percutaneous coronary intervention (PCI), or pharmacologically with fibrinolysis. Regardless of the reperfusion strategy selected, the appropriate use of anticoagulant therapy is critical to its success. There have been a number of clinical trials evaluating the different anticoagulants in patients with STEMI, as well as recent updates to the guidelines for management of patients with STEMI and on the use of PCI. When making clinical decisions on the use of anticoagulant therapy in the management of patients with STEMI, it is important to not only understand the contents of these consensus guidelines but to also have an appreciation of the details of the clinical trials that have evaluated the different anticoagulants. In this review, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with STEMI as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in patients with STEMI undergoing either mechanical or pharmacologic reperfusion.",
keywords = "acute coronary syndrome, anticoagulation, bivalirudin, cardiology, coronary artery disease, enoxaparin, fibrinolysis, fondaparinux, low-molecular-weight heparin, myocardial infarction, percutaneous coronary intervention, unfractionated heparin",
author = "Dobesh, {Paul P.} and Trujillo, {Toby C.}",
year = "2010",
month = "8",
day = "1",
doi = "10.1177/0897190010366932",
language = "English (US)",
volume = "23",
pages = "335--343",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Anticoagulation in the management of ST-segment elevation myocardial infarction

AU - Dobesh, Paul P.

AU - Trujillo, Toby C.

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Patients with ST-segment elevation myocardial infarction (STEMI) require immediate reperfusion therapy in order to salvage ischemic myocardial tissue and reduce mortality. Reperfusion therapy can be provided mechanically with primary percutaneous coronary intervention (PCI), or pharmacologically with fibrinolysis. Regardless of the reperfusion strategy selected, the appropriate use of anticoagulant therapy is critical to its success. There have been a number of clinical trials evaluating the different anticoagulants in patients with STEMI, as well as recent updates to the guidelines for management of patients with STEMI and on the use of PCI. When making clinical decisions on the use of anticoagulant therapy in the management of patients with STEMI, it is important to not only understand the contents of these consensus guidelines but to also have an appreciation of the details of the clinical trials that have evaluated the different anticoagulants. In this review, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with STEMI as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in patients with STEMI undergoing either mechanical or pharmacologic reperfusion.

AB - Patients with ST-segment elevation myocardial infarction (STEMI) require immediate reperfusion therapy in order to salvage ischemic myocardial tissue and reduce mortality. Reperfusion therapy can be provided mechanically with primary percutaneous coronary intervention (PCI), or pharmacologically with fibrinolysis. Regardless of the reperfusion strategy selected, the appropriate use of anticoagulant therapy is critical to its success. There have been a number of clinical trials evaluating the different anticoagulants in patients with STEMI, as well as recent updates to the guidelines for management of patients with STEMI and on the use of PCI. When making clinical decisions on the use of anticoagulant therapy in the management of patients with STEMI, it is important to not only understand the contents of these consensus guidelines but to also have an appreciation of the details of the clinical trials that have evaluated the different anticoagulants. In this review, the reader will find an evaluation of the current guidelines concerning the use of anticoagulant therapy in patients with STEMI as well as a detailed examination of the literature with critical analysis on issues that should be considered when deciding on the appropriate implementation of anticoagulant therapy in patients with STEMI undergoing either mechanical or pharmacologic reperfusion.

KW - acute coronary syndrome

KW - anticoagulation

KW - bivalirudin

KW - cardiology

KW - coronary artery disease

KW - enoxaparin

KW - fibrinolysis

KW - fondaparinux

KW - low-molecular-weight heparin

KW - myocardial infarction

KW - percutaneous coronary intervention

KW - unfractionated heparin

UR - http://www.scopus.com/inward/record.url?scp=77956257649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956257649&partnerID=8YFLogxK

U2 - 10.1177/0897190010366932

DO - 10.1177/0897190010366932

M3 - Review article

C2 - 21507833

AN - SCOPUS:77956257649

VL - 23

SP - 335

EP - 343

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 4

ER -